Article

FDA accepts new drug application for ophthalmic NSAID

The FDA has approved Alcon Laboratories’ new drug application for nepafenac ophthalmic suspension 0.1% (Nevanac) for the treatment of pain and inflammation associated with cataract surgery. The company anticipates the ophthalmic nonsteroidal anti-inflammatory drug (NSAID) will be commercially available in several weeks.

The FDA has approved Alcon Laboratories’ new drug application for nepafenac ophthalmic suspension 0.1% (Nevanac) for the treatment of pain and inflammation associated with cataract surgery. The company anticipates the ophthalmic nonsteroidal anti-inflammatory drug (NSAID) will be commercially available in several weeks.

The suspension contains a novel prodrug that rapidly penetrates ocular tissues. The approval was based on two multicenter, placebo-controlled studies involving more than 680 patients.

In these studies, more than 80% of patients treated with the nepafenac ophthalmic suspension were pain-free the day after surgery, compared with less than 50% in the placebo group, according to Alcon. After 14 days of treatment, 95% of patients taking the suspension were pain-free, compared with 45% of patients taking the placebo, the company said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.